Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Asthma Clinical criteria: Treatment Phase: First-line prevention The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Population criteria: Patient must be aged 2 to 5 years inclusive. The condition must be frequent intermittent; OR The condition must be mild persistent, AND The treatment must be the single preventer agent, AND The treatment must be an alternative to sodium cromoglycate; OR The treatment must be an alternative to nedocromil sodium.
“Based on biochemical and pharmacological bioassays, it binds with high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway receptors such as t he prostanoid, cholinergic, or β -adrenergic receptor). Montelukast potently inhibits physiologic actions of LTC4, LTD4, and LTE4 at the CysLT1 receptor without any agonist activity.”
“In several studies, the mean plasma half-life of montelukast ranged from 2.7 to 5.5 hours in healthy young adults.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Further studies showed that relatively high concentrations of montelukast competitively inhibit the activity of cytochromes P450 3A4 and 2C9. However, these concentrations are at least 15 fold higher than the peak plasma concentrations attained following a 10-mg oral dose of montelukast. Based on these and other in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast should not be expected to inhibit cytochromes P450, 3A4, 2C9, 1A2, 2A6, 2C19 or 2D6.”